Tumor-Associated Antigens in Rheumatoid Arthritis  Interstitial Lung Disease or Malignancy?

Sargın, Gökhan; Köse, Reyhan; Şentürk, Taşkın

doi:10.5606/archrheumatol.2018.6691

Cited by 16 publications

(16 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, tumor markers have been found to be associated with ILD in CTD. 7,20,21 We found that the levels of serum tumor markers, including CA125, CA153, NSE, and CEA, were lower in pSS-ILD patients than in non-ILD pSS patients. None of these pSS-ILD patients with elevated tumor markers had detectable tumors.…”

Section: Discussionmentioning

confidence: 76%

“…5 The commonly used clinical tumor markers for patients with cancer include carbohydrate antigen (CA) 153 (CA153), CA125, CA19-9, carcinoembryonic antigen (CEA), and neuron-specific enolase (NSE), which involves the malignant lesions of multiple systems and organs, including ovarian cancer, breast cancer, gastric cancer, pancreatic cancer, lung cancer, and some other tumors. 6 However, numerous recent studies have focused on the relationship between the serum tumor markers and the incidence of ILD, 7,8 and have put forward a new concept that the detection of serum tumor markers may be used as risk factors for ILD in patients with connective tissue disease (CTD), such as pSS, rheumatoid arthritis (RA), systemic sclerosis (SSc), and polymyositis/dermatomyositis with a convincing lack of clinical markers.…”

Section: High-resolution Computed Tomography (Hrct)mentioning

confidence: 99%

“…However, numerous recent studies have focused on the relationship between the serum tumor markers and the incidence of ILD, 7 , 8 and have put forward a new concept that the detection of serum tumor markers may be used as risk factors for ILD in patients with connective tissue disease (CTD), such as pSS, rheumatoid arthritis (RA), systemic sclerosis (SSc), and polymyositis/dermatomyositis with a convincing lack of clinical markers.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Increases in tumor markers are associated with primary Sjögren’s syndrome-associated interstitial lung disease

Shi

Han

Guo

et al. 2020

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Aims: Interstitial lung disease (ILD) is the most common type of pulmonary involvement of extraglandular complication in patients with primary Sjögren’s syndrome (pSS), but the diagnosis of pSS-associated ILD (pSS-ILD) is still challenging. This study aimed to investigate the levels of serum tumor markers in pSS patients with or without ILD (pSS-non-ILD) and explore its diagnostic value for pSS-ILD. Methods: A total of 168 pSS-ILD patients and age- and sex-matched 538 pSS-non-ILD were recruited. The levels of peripheral tumor markers, including carbohydrate antigen (CA)153, CA125, CA19-9, carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), β-human chorionic gonadotropin, alpha fetoprotein, CA724, and complexed prostate specific antigen, the clinical manifestations, and general laboratory indicators were measured and collected. Results: Compared with pSS-non-ILD, pSS-ILD patients had higher levels of disease activity indicators, such as EULAR Sjögren’s syndrome disease activity index, ESR, and CRP, and elevated serum levels of tumor markers: NSE, CEA, CA125, and CA153. The serum levels of CA153 [odds ratio (OR) = 4.521, 95% confidence interval (CI) = [1.871, 10.928)] and CEA [OR = 2.879, 95% CI = (1.305, 6.353)] were significantly correlated with the onset of SS-ILD. CA153 was the only tumor marker with area under receiver operating characteristic curve (AUC) over 0.7 [AUC = 0.743, 95% CI = (0.70, 0.79)]. Conclusion: Tumor markers increased in serum of pSS-ILD patients. Higher CA153 levels are significantly correlated to the increased risk of ILD in patients with pSS and may be directly involved in the pathogenesis of pSS-ILD. Serum CA153 had the best diagnostic value in those tumor markers for pSS-ILD without malignancy.

show abstract

Section: Discussionmentioning

confidence: 76%

Section: High-resolution Computed Tomography (Hrct)mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Increases in tumor markers are associated with primary Sjögren’s syndrome-associated interstitial lung disease

Shi

Han

Guo

et al. 2020

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

show abstract

“…Shi et al observed that higher serum CA153 and neuron-specific enolase (NSE) levels are significantly related to increased risk of ILD in patients with primary Sjögren’s syndrome (pSS) rather than the EULAR Sjögren’s syndrome disease activity index (ESSDAI) [ 8 ]. Elevated CA125 was associated with a sixfold increase in the odds of ILD in RA [ 9 ].…”

Section: Inroductionmentioning

confidence: 99%

Serum KL-6, CA19-9, CA125 and CEA are Diagnostic Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease in the Chinese Population

et al. 2021

View full text Add to dashboard Cite

Introduction This study aimed to evaluate the role of tumor marker carbohydrate antigen (CA) 125 (CA125), CA19-9, carcinoembryonic antigen (CEA) and Krebs von den Lungen-6 (KL-6) in the diagnosis and determination of the severity of interstitial lung disease (ILD) in rheumatoid arthritis (RA) patients. Methods A retrospective analysis was performed. Fifty RA patients (24 patients with ILD and 26 patients without ILD), 10 healthy subjects and 14 patients with other connective tissue disease-associated interstitial lung disease were included. Serum levels of KL-6 and tumor markers CA19-9, CA125 and CEA were measured. Chest HRCT of patients with ILD was scored quantitatively according to the degree of fibrosis. Data on the C-reactive protein, erythrocyte sedimentation rate, rheumatoid factors and anti-cyclic peptide containing citrulline (anti-CCP) were also collected. Results Serum levels of KL-6, CA19-9, CA125 and CEA in the RA-ILD group were significantly higher than those in the RA-no-ILD group. The serum KL-6 level was positively correlated with the HRCT fibrosis score ( r = 0.63, p = 0.002). The logistic regression analysis showed that CA19-9 and smoking were associated with RA-ILD [OR = 1.118, 95% CI = (1.038, 1.204), p = 0.003 for CA19-9, OR = 14.969, 95% CI = (1.750, 128.043), p = 0.013 for smoking]. Conclusions KL-6 level and tumor markers were elevated in RA-ILD, and strongly associated with the severity of ILD, supporting their value as pathogenically relevant biomarkers, which can contribute to noninvasive detection of this extra-articular disease complication.

show abstract

“…Nevertheless, reports concerning the diagnostic performance of biomarkers on lung cancer were still inconsistent and even contradictory, thus the markers are underutilized in clinical practice in general. In addition, elevation of some of the biomarkers were found not only in lung cancer, but also they were detected abnormally in other diseases [8][9][10]. It is still unclear what the optimal combination of tumor biomarkers to enhance the diagnostic e cacy, the ability of tumor markers in characterizing the histological type of lung cancer are still unclari ed [11].…”

Section: Introductionmentioning

confidence: 99%

Histological specificity and diagnostic performance of a six-biomarker panel of lung cancer: An evaluation of a geographically-based multicenter study in China

Li¹,

Zhang²,

Jiang³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Lung cancer is the most common neoplasm among all cancers worldwide. Early diagnosis with minimal invasive procedures is ideal for lowering the patients’ burden and increasing survival rates. The value of serum tumor biomarkers used in lung cancer screening is still controversial in clinical practice.Methods: Serum levels of ProGRP, NSE, SCC-Ag, CEA, CYFRA21-1, and HE4 were measured using the chemiluminescence immunoassay in apparently healthy Chinese individuals, as well as in those with benign non-cancerous diseases, lung cancer patients, and those suffering other types of malignancies. Data was analyzed utilizing the SPSS version 18.0 statistical software. Results: All 6 serum biomarkers in lung cancers were significantly higher than in benign non-cancerous diseases and healthy controls. HE4 levels in benign diseases were significantly higher than in healthy controls. SCC-Ag, CEA, and CYFRA21-1 levels in lung cancers were significantly higher than in other malignancies. ProGRP and NSE levels in SCLC were significantly higher than in other histologic types; SCC-Ag and CYFRA21-1 levels in SCC were significantly higher than in other histologic types; the HE4 level in SCLC was also significantly higher than in SCC and adenocarcinoma, while adenocarcinoma had the highest serum CEA level comparing to SCC and SCLC. Serum ProGRP, NSE, and HE4 in SCLC were significantly higher than in NSCLC, SCC-Ag level in NSCLC was significantly higher than in SCLC. All biomarkers in advanced stages were significantly higher than in lower stages. NSE, HE4, and ProGRP presented relative high performance in SCLC. CYFRA21-1, HE4, and SCC-Ag indicated relative high performance in SCC. All biomarkers had relatively low performance on adenocarcinoma histologic type. The best performance of 2-marker combination was SCC-Ag+CYFRA21-1 for SCC, ProGRP+NSE for SCLC, CEA+CYFRA21-1 for adenocarcinoma. A combination of SCC+CEA+CYFRA21-1 gained highest performance for NSCLC.Conclusions: A 6-biomarker panel had capability on characterizing lung cancer and presented high performance individually and combinatorically on different histologic types of the neoplasm. HE4 showed high sensitivity to all histologic types of the malignancy; however, one should be cautious since its level also increased in benign non-cancerous diseases.

show abstract

Tumor-Associated Antigens in Rheumatoid Arthritis Interstitial Lung Disease or Malignancy?

Cited by 16 publications

References 20 publications

Increases in tumor markers are associated with primary Sjögren’s syndrome-associated interstitial lung disease

Increases in tumor markers are associated with primary Sjögren’s syndrome-associated interstitial lung disease

Serum KL-6, CA19-9, CA125 and CEA are Diagnostic Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease in the Chinese Population

Histological specificity and diagnostic performance of a six-biomarker panel of lung cancer: An evaluation of a geographically-based multicenter study in China

Contact Info

Product

Resources

About